A detailed history of Virtu Financial LLC transactions in Sellas Life Sciences Group, Inc. stock. As of the latest transaction made, Virtu Financial LLC holds 79,241 shares of SLS stock, worth $106,975. This represents 0.01% of its overall portfolio holdings.

Number of Shares
79,241
Previous 63,843 24.12%
Holding current value
$106,975
Previous $76,000 30.26%
% of portfolio
0.01%
Previous 0.01%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 20, 2024

BUY
$1.08 - $1.39 $16,629 - $21,403
15,398 Added 24.12%
79,241 $99,000
Q2 2024

Aug 09, 2024

BUY
$1.06 - $1.63 $25,878 - $39,794
24,414 Added 61.92%
63,843 $76,000
Q1 2024

May 20, 2024

SELL
$0.51 - $1.55 $10,447 - $31,751
-20,485 Reduced 34.19%
39,429 $40,000
Q4 2023

Feb 26, 2024

BUY
$0.88 - $1.57 $36,037 - $64,294
40,952 Added 215.97%
59,914 $64,000
Q3 2023

Nov 14, 2023

BUY
$1.42 - $1.83 $26,926 - $34,700
18,962 New
18,962 $31,000
Q4 2022

Feb 15, 2023

BUY
$1.8 - $5.41 $33,082 - $99,430
18,379 New
18,379 $43,000
Q1 2022

May 17, 2022

SELL
$4.73 - $7.18 $65,912 - $100,053
-13,935 Closed
0 $0
Q4 2021

Feb 17, 2022

BUY
$5.36 - $9.53 $74,691 - $132,800
13,935 New
13,935 $77,000
Q2 2021

Sep 17, 2021

SELL
$7.19 - $13.71 $104,923 - $200,070
-14,593 Closed
0 $0
Q1 2021

May 19, 2021

SELL
$5.5 - $11.71 $26,702 - $56,852
-4,855 Reduced 24.96%
14,593 $125,000
Q4 2020

Feb 24, 2021

BUY
$2.45 - $17.66 $47,647 - $343,451
19,448 New
19,448 $113,000
Q3 2020

Dec 11, 2020

SELL
$1.88 - $3.58 $62,596 - $119,199
-33,296 Closed
0 $0
Q2 2020

Aug 07, 2020

BUY
$1.53 - $3.93 $50,942 - $130,853
33,296 New
33,296 $98,000

Others Institutions Holding SLS

About SELLAS Life Sciences Group, Inc.


  • Ticker SLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 20,551,900
  • Market Cap $27.7M
  • Description
  • SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the tr...
More about SLS
Track This Portfolio

Track Virtu Financial LLC Portfolio

Follow Virtu Financial LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Virtu Financial LLC, based on Form 13F filings with the SEC.

News

Stay updated on Virtu Financial LLC with notifications on news.